Lenalidomide Maintenance in Plasma Cell Myeloma
This is a Phase 2 study to assess the good and bad effects of maintenance therapy on patients who have been treated for myeloma and no longer show signs of this type of cancer.
Plasma Cell Myeloma
DRUG: Lenalidomide
progression-free survival, PFS is defined as time of start of treatment to time of progression or death, whichever occurs first., 5 years
This is a Phase 2 study to assess the good and bad effects of maintenance therapy on patients who have been treated for myeloma and no longer show signs of this type of cancer.